Treating drug-resistant tuberculosis in a low-intensity chronic conflict setting in India

Table 1 Clinical characteristics and treatment outcome details of pulmonary, drug-resistant TB patients in Chhattisgarh-Andhra Pradesh border, India

Case	Age	Sex	State of origin	AFB smear result	Resistance profile DST	TB Resistance pattern	Treatment regimen	Duration (months)	Adverse events	Outcome
1	50	M	AP	Pos	S,H,Z	PDR	Inj Km/Mx/ R/E	14	Oto-toxicity	Cured
2	40	F	AP	Neg	H	Mono-R	Inj Km/Mx/ R/E/Z	14	-	Cured
3	25	M	AP	Neg	H,Z	PDR	-	-	-	LTFU
4	45	M	AP	Pos	S,H,R,Z,E	MDR	Inj Cm/Mx/ Eto/Cs/PAS	24	GI dist^a	Cured
5	40	M	CG	Pos	H	Mono-R	Inj Cm/Mx/ R/E/Z	12	Psych^b	Cured
6	45	M	CG	Pos	S,H,R,Z	MDR	Inj Cm/Mx/ Eto/Cs/PAS	24	-	Cured
7	45	M	CG	Pos	S,H,Eto	PDR	Inj Cm/Mx/ R/E/Z	13	Renal dys^c	Cured
8	45	M	CG	Pos	S,H	PDR	Inj Cm/Mx/ R/E/Z	13	-	Cured
9	45	F	CG	Pos	H,R	MDR	Inj Km/Lx/ Eto/Cs/E/Z	7	-	On-treatment^┼
10	13	F	CG	Pos	H	Mono-R	H/R/Z/E	6	-	On-treatment^┼
11	35	M	AP	Neg	H,R,Z	MDR	Inj Km/Lx/ Eto/Cs/E/Z	7	-	On-treatment^┼
12	25	M	CG	Pos	H,R	MDR	-	-	-	Died
13	60	M	AP	Pos	H	Mono-R	-	-	-	Refused treatment

M: Male, F: Female, AP: Andhra-Pradesh, CG: Chhattisgarh, Pos: Positive, Neg: Negative.
^aGI dist: Gastro-intestinal disturbance, ^bPsych: Psychological complaints, ^cRenal dys : Renal dysfunction.
Mono-R: Mono-resistance tuberculosis; defined as drug-resistant TB case whose recovered M. tuberculosis isolate is resistant to one first line anti-TB drug.
PDR: Poly-resistance tuberculosis; defined as drug-resistant TB case whose recovered M. tuberculosis isolate is resistant to more than one first line anti-TB drug, but not MDR-TB.
MDR: Multi-drug resistant tuberculosis; defined as drug-resistant TB case whose recovered M. tuberculosis isolate is resistant in-vitro to isoniazid and rifampicin with or without resistance to other anti-tubercular drugs based on DST results.
S: Streptomycin, H: Isoniazid, R: Rifampicin, Z: Pyrazinamide, E: Ethambutol, Eto: Ethionamide, Km: Kanamycin, Mx: Moxifloxacin, Cm: Capreomycin, Cs: Cycloserine, PAS: Para-amino salicylic acid, Lx: Levofloxacin.
LTFU: Lost to follow up.
^┼Culture negative at end of intensive phase; currently in continuation phase.

ISSN: 1752-1505